Global University venturing has awarded the 2018 Deal of the Year Award to UCLB spinout, Orchard Therapeutics; a biotechnology company dedicated to transforming the lives of patients with rare disorders, through innovative gene therapies.
Orchard Therapeutics received the award for an oversubscribed $110million series B round which completed in December last year. The round was co-led by Baillie Gifford and ORI Capital, alongside contributions from a number of investors, including the UCL Technology Fund.
Based on research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher at the UCL Institute of Child Health, Orchard Therapeutics was founded in 2015 through a partnership between UCLB and F Prime Capital Partners.
Read more about this story here.